Point72 Asset Management
RLMD icon

Point72 Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Point72 Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-70,000
Closed -$2.59M – 1750
2022
Q3 		$2.59M Buy
+70,000
New +$1.94M 0.01% 870

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management's RLMD Position: Q1 2026 in Review

Point72 Asset Management increased its Relmada Therapeutics (RLMD) stake by 169% in Q1 2026, buying an estimated $1.5M and bringing the position to 504,820 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

Point72 Asset Management first reported a position in RLMD in Q4 2019 and has held it in 15 quarters since. The position peaked at $35.4M in Q1 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Point72 Asset Management held 504,820 shares of Relmada Therapeutics worth $3.51M as of Q1 2026.
  • Point72 Asset Management bought 317,443 Relmada Therapeutics shares in Q1 2026, an estimated $1.5M.
  • Relmada Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1932 holding.
  • Point72 Asset Management first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 15 quarters since.
  • Point72 Asset Management's Relmada Therapeutics position peaked at $35.4M in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.